CELT ACD VASCULAR CLOSURE DEVICE
Vasorum, Ltd. · Decision date Oct 30, 2026
What did the FDA approve?
FDA recorded an approval decision on 2026-10-30 for P150006/S009, a Special (Immediate Track) PMA supplement to Vasorum, Ltd.'s CELT ACD VASCULAR CLOSURE DEVICE. The supplement reason is listed as a labeling change covering indications, instructions, shelf life or tradename. The recorded statement describes changes to the Instructions for Use labeling for a limited number of CELT ACD PLUS 5F device lots.
This action amends labeling for specified lots of the CELT ACD PLUS 5F device; it is not a new approval of the whole system, and the source does not identify which labeling element changed, the affected lot numbers, or any clinical effect. The device is categorized as a hemostasis, vascular device under product code MGB in the Cardiovascular specialty. No supporting documents were included, so the revised labeling text and its scope remain unverified here.
FDA approval order statement
changes to the Instructions for Use labeling for a limited number of CELT ACD PLUS 5F device lots
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 30, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150006/S009
- Regulatory pathway
- PMA supplement
- Applicant
- Vasorum, Ltd.
- Product code
- MGB
- Decision code
- APPR
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Vasorum, Ltd.
- Product code
- MGB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150006 · Original PMA
CELT ACD VASCULAR CLOSURE DEVICE
P150006/S009 received
Application receipt date recorded by FDA.
P150006/S009 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P150006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Vasorum, Ltd. | PMA approval | Jul 20, 2016 | FDA |
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
VASCADE 5F Vascular Closure SystemP120016/S043 | Cardiva Medical, Inc. | PMA supplement | Sep 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vasorum, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2012 Orchard Ave., Citywest Business Campus, Dublin, 24
Sources and methodology
- Original FDA record: P150006/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


